Glucagon-like peptide-1 (GLP-1) agonists, which improve insulin secretion, decrease glucagon secretion, increase satiety (and therefore decrease food intake), and may have beneficial effects on beta-cell function, represent an important addition to treatment options
doi:10.1016/j.physbeh.2008.07.018 231
The global microfluidics in oncology market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034.
I reached my highest weight ever at 270+ pounds and kept telling myself I was okay with it, but eventually I realized I wanted to make a change
Collectively, in the end, GLP-1RAs exasperate the primary cause of obesity: Metabolic Syndrome
Proper nutrition support is essential not only to preserve bone and muscle and prevent micronutrient deficiencies but also to establish healthy lifestyle habits that support long-term weight management, even after discontinuing a GLP-1 medication